Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New scan could spot hidden heart risk in kidney patients

NCT ID NCT07585695

Diagnosis Sponsor: University Hospital, Grenoble Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a special heart scan (CZT-SPECT) can better predict heart attacks, strokes, and heart failure in people with chronic kidney disease. Current tests often miss heart problems in these patients. The study will follow 283 participants for two years to see if the scan's results match up with who has heart events.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CZT-SPECT imaging (a type of heart scan)
What this could lead to
If successful, this could lead to a better, non-invasive way to identify kidney patients at highest risk of heart problems, allowing earlier treatment.
What could go wrong
This is an observational study, not a treatment trial. The scan may not prove more useful than current methods, and results may not apply to all kidney patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 283 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients from the University Hospital of Grenoble

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female patients aged over 18 years * Affiliated with the French social security system * Patients at renal risk based on albuminuria (Alb) and glomerular filtration rate (GFR \< 30 mL/min/1.73 m², or GFR \< 45 mL/min/1.73 m² with albuminuria \> 30 mg/g, or GFR \< 60 mL/min/1.73 m² with albuminuria \> 300 mg/g) * Patients undergoing, independently of the research and according to the clinician's decision as part of standard care, CZT-SPECT myocardial perfusion imaging with coronary flow reserve measurement for cardiovascular risk assessment * Having expressed no objection to participation in this study Exclusion Criteria: * Legally protected adult (Article L1121-8 of the French Public Health Code) * Person deprived of liberty (Article L1121-8 of the French Public Health Code) * Pregnant woman * Patient who has undergone a normal coronary exploration within the past year

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney disease (CKD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic kidney disease (CKD) Coronary artery disease (CAD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU Grenoble Alpes

    La Tronche, France, 38700, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.